uniQure is a gene therapy biotechnology company with reported revenue growth of 127% year-over-year and analyst consensus implying 40% upside to $34.01, but a cash burn rate of -573% of revenue, a quality score of 1.8 out of 10, and operating margin compression signal that the growth is not yet converting into sustainable financial performance.
Thesis pillars
- Margin Compression Value Trap Signal→Stable
- Exceptional Revenue Growth Rate→Stable
- Substantial Cash Burn Quality Concern→Stable
- +1 more pillar — see the Why tab for full reasoning
uniQure N.V. (QURE) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $38.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.76; Below-average business quality.
uniQure is a clinical-stage gene therapy company whose lead candidate, AMT-130, is being developed as a one-time treatment for Huntington's disease using the company's proprietary miQURE gene-silencing platform. Following positive Phase I/II topline data in September 2025, the... Read more
Sell if holding. Engine safety override at $38.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.76; Below-average business quality. Chart setup: Oversold RSI 23, near Bollinger lower, volume surge. Score 5.8/10, moderate confidence.
Passes 5/8 gates (positive momentum, favorable risk/reward ratio, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
About uniQure N.V.
About uniQure N.V.
uniQure's lead gene-therapy candidate, AMT-130 for Huntington's disease, showed a statistically significant 75% slowing of disease progression on the cUHDRS scale at 36 months in high-dose patients from its Phase I/II trial, reported in September 2025. Despite that data and Breakthrough Therapy designation granted in April 2025, the FDA told the company in December 2025 and again in March 2026 that the Phase I/II results are insufficient to support a marketing application.
uniQure has no approved products and is developing four gene-therapy candidates built on its proprietary miQURE gene-silencing platform: AMT-130 for Huntington's disease, AMT-260 for refractory mesial temporal lobe epilepsy (which uses an AAV9 vector exclusively licensed from Regenxbio), AMT-191 for Fabry disease, and AMT-162 for SOD1-ALS, the last of which had enrollment voluntarily paused in September 2025 after a dose-limiting toxicity event. The company funds this pipeline through equity offerings — $70.1 million in January 2025 and $323.7 million in September 2025 — and a $175.0 million senior secured term loan facility with Hercules Capital carrying a floating rate of 9.45% as of December 31, 2025, with an additional $100.0 million tranche available only if AMT-130 wins BLA approval before June 2027.
Show full overview
uniQure's near-term future rests almost entirely on AMT-130: the 10-K states the company is dependent on the success of its lead clinical candidate, and that dependency became more acute in early 2026, after the FDA's Type A meeting minutes said Phase I/II data compared to an external control cannot serve as primary evidence of effectiveness and recommended a prospective, randomized, double-blind, sham surgery-controlled study instead. Because a second Hercules loan tranche of $100.0 million is contingent on BLA approval of AMT-130 before June 2027, the same regulatory setback that delays commercialization also narrows uniQure's access to already-committed financing.
See also: Healthcare · Biotechnology
From uniQure N.V.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-29Recent Developments — uniQure N.V.
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga Jul 30, 2026 neutral
- NEWS Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75 — benzinga Jul 30, 2026 positive
- NEWS Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target — benzinga Jul 30, 2026 positive
- NEWS Barclays Maintains Overweight on uniQure, Lowers Price Target to $60 — benzinga Jul 30, 2026 neutral
- NEWS uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate — benzinga Jul 29, 2026 negative
Generated 2026-07-31T00:14:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineAMT-13010-K Item 1A: 'We are dependent on the success of our lead clinical product candidate, AMT-130, for the treatment of Huntington's disease.'
Material Events(8-K, last 90d)
- 2026-06-15Item 5.02LOWAt the June 10, 2026 Annual General Meeting, shareholders approved an amendment to the 2014 Share Incentive Plan increasing shares reserved for issuance, as previously approved by the Board on April 14, 2026. Routine equity-plan matter, not an executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.99: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.76; Below-average business quality. Chart setup: Oversold RSI 23, near Bollinger lower, volume surge. Prior stop was $34.28. Score 5.8/10, moderate confidence.
Take-profit target: $56.24 (+53.4% upside). Prior stop was $34.28. Stop-loss: $34.28.
Concentration risk — Pipeline: AMT-130; Quality below floor (1.8 < 4.0).
uniQure N.V. trades at a P/E of N/A (forward -12.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover QURE with a consensus score of 4.1/5. Average price target: $65.
What does uniQure N.V. do?uniQure is a clinical-stage gene therapy company whose lead candidate, AMT-130, is being developed as a one-time...
uniQure is a clinical-stage gene therapy company whose lead candidate, AMT-130, is being developed as a one-time treatment for Huntington's disease using the company's proprietary miQURE gene-silencing platform. Following positive Phase I/II topline data in September 2025, the FDA told uniQure in December 2025 and again in March 2026 that the data are insufficient to support a marketing application, recommending a randomized, controlled Phase III study instead.